← Back to Clinical Trials
Recruiting Phase 3 NCT07177352

NCT07177352 Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07177352
Status Recruiting
Phase Phase 3
Sponsor Hoffmann-La Roche
Condition Alzheimers Disease
Study Type INTERVENTIONAL
Enrollment 13,000 participants
Start Date 2025-07-02
Primary Completion 2035-07-31

Trial Parameters

Condition Alzheimers Disease
Sponsor Hoffmann-La Roche
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 13,000
Sex ALL
Min Age 50 Years
Max Age 90 Years
Start Date 2025-07-02
Completion 2035-07-31
Interventions
No Intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.

Eligibility Criteria

Inclusion Criteria: \- Report of objective or subjective memory concerns (by the participant and/or their informant) within the last year with or without a previous clinical diagnosis of MCI or dementia due to AD. Exclusion Criteria: * Dependency in basic activities of daily living (bADLs) due to cognitive impairment * Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted) * Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD * History of severe, clinically significant central nervous system trauma * Any serious medical condition that precludes a participant's safe participation and completion of a clinical study

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology